Prof. Gao Xueyun’s team focuses on the intersection of chemical biology and biomedicine. Based on the use of metal clusters, they have made important breakthroughs in the fields of the precise cancer diagnosis and the development of innovative antiviral drugs. Relevant research results have been published in international journals.

Theteam has pioneered a series of metal cluster probes suitable for the analysis of malignant tumor proteins, and has obtained a US patent. Based on this, a systematic analysis strategy for detecting the risk of invasive and metastatic primary lung cancer has been developed at the level of body fluid single cells and at tissue level, with the additional employment ofin vivoimaging using patented probes.

Prof. Gao's team has made a breakthrough in the creation of a drug for the treatment of COVID-19. The COVID-19 treatment drug targets the conserved main protease of the coronavirus and is expected to overcome the risk of the low efficiency or ineffectiveness of vaccines or antibody drugs against mutant strains, and suppress over-reaction of the immune system through regulation of it. Patents for the technology have been applied for in China and the US, and will enter major countries around the world through PCT. In addition, BJUT and Pharmaceutical Co., Ltd. have signed a formal contract, which will greatly promote the commercialization of the team's COVID-19 treatment drug project.